Combination therapy for prophylaxis and/or treatment of benign p

Details Combination therapy for prophylaxis and/or treatment of benign p Combination therapy for prophylaxis and/or treatment of benign p

1993-12-15

1997-01-21

Kishore, Gollamudi S.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514177, 514178, 514646, 514647, A61K 3156

Patent

active

055959857

ABSTRACT:
A combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia in susceptible warm-blooded animals which comprises administering a combination of two or more compounds selected from the group consisting of an inhibitor of 5.alpha.-reductase activity, an antiestrogen, an inhibitor of aromatase activity, an inhibitor of 17.beta.-hydroxysteroid dehydrogenase activity and, in some cases, an anti-androgen and/or an LHRH agonist. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such compositions are disclosed.

REFERENCES:
patent: 4055641 (1977-10-01), Benson et al.
patent: 4310523 (1982-01-01), Neumann
patent: 4472382 (1984-09-01), Labrie
patent: 4596797 (1986-06-01), Schweikert et al.
patent: 4659695 (1987-04-01), Labrie
patent: 4732897 (1988-03-01), Cainelli
patent: 4760053 (1988-07-01), Labrie
patent: 4775660 (1988-10-01), Labrie
patent: 4888336 (1989-12-01), Holt
patent: 5023234 (1991-06-01), Labrie
patent: 5053403 (1991-10-01), Orentreich
patent: 5064813 (1991-11-01), Labrie
patent: 5204337 (1993-04-01), Labrie
patent: 5364847 (1994-11-01), Labrie
patent: 5372996 (1994-12-01), Labrie
patent: 5393785 (1995-02-01), Labrie
McConnell et al., J. Urol. 141: 239A (1989).
Stoner, E., Lecture, 84th AUA Annual Meeting, Dallas May 8, 1989.
Merck L 652,931, Proc. 71st Annal Meeting of Endocr. Soc. abst. #1165, p. 314 (1989).
Gormley et al., Proc. 71st Annual Meeting of Endocr. Soc. abst. #1225, p. 329 (1989).
Imperato-McGinely et al., Proc. 71st Annual Meeting of Endo Soc., abst. #1639, p. 432 (1989).
Geller and Franson, Proc. 71st Annal Meeting of Endocr. Soc. abst. #1640, p. 432 (1989).
Tenover et al., Proc. 71st Annual Meeting of Endocr. Soc. abst. #583, p. 169 (1989).
Toomey et al., Proc. 71st Annual Meeting of Endo. Soc., abst. #1226, p. 329 (1989).
Walsh and Wilson, J. Clin. Invest. 57: 1093-1097 (1976).
Robinette et al., Invest. Urol. 15: 425-432 (1978).
Moore et al., J. Clin. Invest. 63: 351-357 (1979).
Tunn et al., Urol. Int. 35: 125-140 (1980).
Funke et al., Acta Endocrinol 100: 462-472 (1982).
Di Silverio et al., Excerpta Medica, pp. 117-125 (1986).
Schweikert et al., J. Clin. Endocrinol. Metab. 40: 413-417 (1975).
Folker and James, J. Steroid Biochem. 49:687-690 (1983).
Longcope et al., J. Clin. Endocrinol. Metab. 46:146-152 (1978).
Lacoste and Labrie, unpublished datas.
Stone et al., The Prostate 9:311-318 (1986).
Stone et al., Urol. Res. 15:165-167 (1987).
Wilson, N. Engl. J. Med. 317:628-629 (1987).
Wendel et al., J. Urol. 108:116-119 (1972).
Auclair et al., Biochem. Biophys. Res. Commun. 76:855-862 (1977).
Auclair et al., Endocrinology 101:1890-1893 (1977).
Labrie et al., Int. J. Andrology, suppl. 2 (V. Hansson, ed.), Scriptor Publisher APR, pp. 303-318 (1978).
Labrie et al., J. Andrology 1:209-228 (1980).
Tremblay and Belanger, Contraception 30:483-497 (1984).
Tremblay et al., Contraception 30:585-598 (1984).
Dube et al., Acta Endocrinol. (Copenh) 116:413-417 (1987).
Lacoste et al., Mol. Cell. Endocrinol. 56:141-147 (1988).
White, Ann. Surg. 22:1-80 (1985).
Faure et al., Fertil. Steril. 37:416-424 (1982).
Labrie et al., Endocrine Reviews 7:67-74 (1986).
Huggins and Stevens, J. Urol. 43:705-714 (1940).
Bruchovsky and Wilson, J. Biol. Chem. 243:2012-2021, 1968.
Peters and Walsh, N. Engl. J. Med. 317:599-604 (1987).
Gabrilove et al., J. Clin. Endocrinol. Metab. 64:1331-1333 (1987).
Neri et al., Endocrinology, 82:311-317 (1968).
Neri et al., Investigative Urology, 10:123-130 (1972).
Tunn et al., Acta Endocrinol. (Copenh.) 19:373-384 (1979).
Seguin et al., Mol. Cel. Endocrinol., 21:37-41 (1981).
Lefebvre et al., The Prostate 3:569-578 (1982).
Marchetti and Labrie, J. Steroid Biochem, 29:691-698 (1988).
Wilson Handbook of Physiology 5 (sec. 7), pp. 491-508 (1975).
Tunn et al., Invest. Urol. 18:289-292 (1980).
Scott and Wade, J. Urol. 101:81-85 (1969).
Caine et al., J. Urol. 114:564-568 (1975).
Stone et al., J. Urol. 141:240A (1989).
Clejan et al., J. Urol. 141:534A (1989).
Poyet and Labrie, Mol. Cell. Endocrinol. 32:283-288 (1985).
Labrie et al., J. Steroid Biochem. 28:379-384 (1987).
Jacobi et al., Endocrinology 102:1748-1755 (1978).
Brooks et al. Endocrinology 109:830 (1981).
Brooks et al., Prostate 3: 35 (1982).
Wenderoth et al., Endocrinology 113, 569-573 (1983).
Brooks et al., Proc. Soc. Exp. Biol. Med. 169: 67 (1982).
DeSilverio, et al., "Anti-estrogens and anti-androgens in human benign prostatic hyperplasia", Ipertrofia Prostatica Benigna, Excerpta Medica, Oct. 18-19, 1985, pp. 117-125.
Wilson, J. D., "Metabolism of testicular androgens", Handbook of Physiology-Endocrinology V, Sec. 7, 1975, pp. 491-508.
Brooks, et al., "Effect of a New 5.alpha.-Reductase Inhibitor on Size, Histologic Characteristics, and Androgen Concentrations of the Canine Prostate", The Prostate, 3:35-44, 1982.
Cancer Res. 48, pp. 834-838 (1988).

Affiliated with

Also associated with

Rating

Combination therapy for prophylaxis and/or treatment of benign p does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy for prophylaxis and/or treatment of benign p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for prophylaxis and/or treatment of benign p will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2324296